Neuropace, Inc. Common Stock
NPCENeuroPace, Inc. (NPCE) is a medical device company specializing in the development and commercialization of responsive neurostimulation systems for the treatment of neurological disorders, primarily epilepsy. Their flagship product, the RNS System, is designed to detect and respond to abnormal brain activity in real-time, aiming to reduce seizure frequency and improve patient quality of life. Founded in 1997, NeuroPace focuses on innovations in neuromodulation technology to address unmet needs in neurological healthcare.
Company News
NeuroPace (NPCE) shares rose nearly 1% following the company's earnings release showing strong Q4 2025 performance. The medical device specialist reported revenue of $26.6 million (24% YoY growth) and narrowed its net loss to $2.7 million, beating analyst expectations on both metrics. The company's flagship RNS System epilepsy treatment device dr...
NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.
NeuroPace, a medical device company focused on epilepsy treatment, announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference.
The neuroscience market is rapidly expanding, driven by growing awareness of neurological disorders and advancements in medical research and technology. Key investments from public and private sectors, along with the integration of advanced technologies like Brain-Computer Interfaces, AI, and machine learning, are transforming the neuroscience la...
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
